A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
NCT ID: NCT03195478
Last Updated: 2025-09-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
37 participants
INTERVENTIONAL
2017-08-02
2024-01-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
NCT05134948
A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
NCT02593786
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
NCT03792750
A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China
NCT04825873
Study of Relatlimab in Combination With Nivolumab in Chinese Participants
NCT05498480
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nivo/Ipi Combination Therapy A
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Nivo/Ipi Combination Therapy B
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Nivo/Ipi Combination Therapy C
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Nivo/Ipi Combination Arm D
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* One prior anti-cancer therapy that did not work or documented refusal to receive chemotherapy or biological therapy
Exclusion Criteria
* Active, known or suspected autoimmune disease or infection
* Positive blood screen for chronic infection of hepatitis B or hepatitis C (HCV antibody positive unless HCV RNA is negative)
* Prior immuno-oncology therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0015
Beijing, Beijing Municipality, China
Local Institution - 0001
Beijing, Beijing Municipality, China
Local Institution
Guangzhou, Guangdong, China
Local Institution - 0012
Guangzhou, Guangdong, China
Local Institution - 0011
Harbin, Heilongjiang, China
Local Institution
Zhengzhou, Henan, China
Local Institution - 0021
Wuhan, Hubei, China
Local Institution - 0020
Xi'an, Shan1xi, China
Local Institution - 0016
Shanghai, Shanghai Municipality, China
Local Institution - 0018
Chengdu, Sichuan, China
Local Institution - 0004
Tianjin, Tianjin Municipality, China
Local Institution - 0013
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA209-672
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.